Last reviewed · How we verify
100% O2
100% O2, developed by the Medical University of Vienna, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | 100% O2 |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exercise and Carotid Artery Function in Metabolic Syndrome
- Improving Visual Field Deficits With Noninvasive Brain Stimulation (NA)
- The Effects of Three Different Anesthetic Methods on Postoperative Agitation (NA)
- Cerebral Oxygen Saturation Monitoring In Cardiac Surgery (COSMICS) (NA)
- Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease (NA)
- Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC) (NA)
- Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications (PHASE4)
- Prediction of Hemodynamic Response to Intubation by ANI Variation During Standardized Stimulation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |